MYWOT

Child safety

N/A

Confidence

0%

Trustworthiness

N/A

Confidence

0%

MALICIOUS CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Aveooncology.com most likely does not offer any malicious content.

  • Siteadvisor

    Safety status

    N/A

  • SAFEBROWSING

    Safety status

    Safe

  • Phishtank

    Safety status

    N/A

Secure connection support

HTTPS

Aveooncology.com provides SSL-encrypted connection.

ADULT CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Aveooncology.com most likely does not offer any adult content.

Audience

  • Gender

    The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

    Men

    15%

    Women

    99%

Popular pages

  • Aveo Oncology | An LG Chem company

    Click Here To View Our ASCO Poster: TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal...

  • Corporate Overview | Aveo Oncology

    get_sidebar(); ?> We are united in our efforts to provide patients with reasons to believe that they can receive effective treatments while carrying on with their daily living. AVEO is an oncolog...

  • Pipeline | Aveo Oncology

    **Partnered with Bristol Myers Squibb ***Partnered with AstraZeneca AVEO Oncology is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a bet...

  • Press Releases | Aveo Oncology

    September 16, 2024 Download PDF – TiNivo-2 FOTIVDA® (tivozanib) monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line immune checkpoint inhibito...

  • Our Medicine | Aveo Oncology

    get_sidebar(); ?> Approved by the U.S. Food and Drug Administration for the treatment of adults patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prio...

  • Tivozanib | Aveo Oncology

    FOTIVDA ® (tivozanib) is an oral, once-daily, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, a...

Open neighbouring websites list